---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-23-000041"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:47:09.836913+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q1 2023 pro forma revenue $40.7M (+7% YoY); exome revenue up 22% to $22.4M; reaffirms FY guidance

## Summary
- Pro forma revenue from continuing ops $40.7M, up 7% YoY; whole exome/genome test revenue $22.4M, up 22%.
- Adjusted gross margin from continuing ops 34%; total company cash burn improved 31% YoY to $58.8M.
- Net loss ($60.4)M; adjusted net loss ($48.9)M, improvement of 23% YoY.
- Reaffirms FY2023 guidance: revenue $205-220M, cash burn $95-110M for continuing ops, profitable in 2025.
- Completed $150M public offering; appointed Devin K. Schaffer as General Counsel.

## SEC filing metadata
- accession: 0001818331-23-000041
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/0001818331-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/smfr-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-23-000041
- JSON: https://secwatch.observer/filing/0001818331-23-000041.json
- Plain text: https://secwatch.observer/filing/0001818331-23-000041.txt

## Key facts
- Earnings Releases
  GeneDx Holdings Corp. reported the first quarter of 2023 results: revenue $40.7 million. Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: $40.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: GeneDx Reports First Quarter 2023 Financial Results and Business Highlights Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/0001818331-23-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.